Literature DB >> 8004751

Quantitation of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration.

A Andersen1, D J Warren, L Slørdal.   

Abstract

A method for measuring cellular concentrations of the anthracycline doxorubicin was developed. The assay involves cell lysis and protein degradation by detergent and proteinase K treatment followed by DNA hydrolysis using DNase I. Prior to high-performance liquid chromatography, samples are deproteinized by the addition of ZnSO4 and methanol. The assay is linear with respect to both the cellular drug content and the number of cells assayed over the ranges tested, and drug recovery is close to 100%. The method has a limit of detection of 50 fmol injected doxorubicin. Within run and between-day coefficients of variation have consistently been found to be in the 5% and 10% range, respectively, in different cell lines exposed to doxorubicin in vitro. The method has been evaluated in analyses of doxorubicin levels in mononuclear blood cells of patients. The assay offers several advantages over commonly used organic extraction techniques and may improve cellular drug monitoring during anthracycline therapy in patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8004751     DOI: 10.1007/BF00685077

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  33 in total

1.  A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.

Authors:  F Y Lee; J Sciandra; D W Siemann
Journal:  Biochem Pharmacol       Date:  1989-11-01       Impact factor: 5.858

2.  Quantitative determination of adriamycin in rat hepatocytes using a volatile extraction buffer, HPLC and fluorescence detection.

Authors:  R Mahdadi; N Pommery; J Pommery; M Lhermitte
Journal:  Biomed Chromatogr       Date:  1987       Impact factor: 1.902

3.  High-performance liquid chromatographic determination of doxorubicin and its metabolites in plasma and tissue.

Authors:  L M Rose; K F Tillery; S M el Dareer; D L Hill
Journal:  J Chromatogr       Date:  1988-03-18

4.  Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.

Authors:  E Reed; R F Ozols; R Tarone; S H Yuspa; M C Poirier
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

5.  Kinetics and sensitivity of daunorubicin in patients with acute leukemia.

Authors:  M W DeGregorio; W M Holleran; B A Macher; C A Linker; J R Wilbur
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Cellular uptake and metabolism of daunorubicin as determined by high-performance liquid chromatography. Application to L1210 cells.

Authors:  R Baurain; A Zenebergh; A Trouet
Journal:  J Chromatogr       Date:  1978-09-21

7.  Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: a method analysis.

Authors:  E Kokenberg; P Sonneveld; K Nooter; K van der Steuyt; B Löwenberg
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  An enhanced ability for transforming adriamycin into a noncytotoxic form in a multidrug-resistant cell line (LZ-8).

Authors:  Y Zhang; K M Sweet; M A Sognier; J A Belli
Journal:  Biochem Pharmacol       Date:  1992-11-03       Impact factor: 5.858

9.  Comparative pharmacokinetics and metabolism of doxorubicin and 4-demethoxy-4'-O-methyldoxorubicin in tumor-bearing mice.

Authors:  F Formelli; R Carsana; C Pollini
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Comparative cardiotoxicity and antitumour activity of doxorubicin (adriamycin) and 4'-deoxydoxorubicin and the relationship to in vivo disposition and metabolism in the target tissues.

Authors:  J Cummings; N Willmott; I More; D J Kerr; J G Morrison; S B Kaye
Journal:  Biochem Pharmacol       Date:  1987-05-01       Impact factor: 5.858

View more
  1 in total

1.  Sodium bicarbonate nanoparticles modulate the tumor pH and enhance the cellular uptake of doxorubicin.

Authors:  Hanan Abumanhal-Masarweh; Lilach Koren; Assaf Zinger; Zvi Yaari; Nitzan Krinsky; Galoz Kaneti; Nitsan Dahan; Yael Lupu-Haber; Edith Suss-Toby; Esther Weiss-Messer; Michal Schlesinger-Laufer; Janna Shainsky-Roitman; Avi Schroeder
Journal:  J Control Release       Date:  2019-01-05       Impact factor: 9.776

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.